Michael Nauck is the Head of Clinical Research at the Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum gGmbH, St. Josef-Hospital (Ruhr-University Bochum) in Germany. From 2000 to 2014, he was Head Physician at the Diabeteszentrum Bad Lauterberg Harz, Germany, a specialised hospital for the care and therapy of patients with diabetes and other metabolic diseases.

He has previously held clinical and research positions at leading German university departments in gastroenterology and endocrinology.

His particular research interest is in the role and impact of gastrointestinal peptide hormones in the physiological and therapeutic stimulation of insulin secretion. He has been acknowledged for major contributions to the development of new therapeutic agents for the treatment of type 2 diabetes based on anti-diabetic properties of the gut hormone GLP-1, e.g. incretin-based glucose-lowering medications (GLP-1 receptor agonists and DPP-4 inhibitors).

Additional areas of interest are spontaneous hypoglycaemia, pancreas transplantation and cardiovascular disease in people with type 2 diabetes and its modulation by different glucose-lowering therapies.

Professor Nauck has been honored with several awards for his research, including the Ferdinand-Bertram Award (1993), the Werner-Creutzfeldt Award (2007), the Paul Langerhans Medal (2012) of the Deutsche Diabetes-Gesellschaft (German Diabetes Association) and the Claude Bernard Medal of the European Association for the Study of Diabetes (2022). He is a member of multiple professional societies, including the German, European and American Diabetes Associations, the International Diabetes Federation and the American Physiological Society.

He has served as a reviewer for all major diabetes journals and has published more than 250 original articles, 150 reviews and book chapters. Michael Nauck has been identified as a “highly cited scientist” (top 1 0/00) by the Web of Science in 2019, 2021, and 2022.

Duality of interest: Professor Nauck has received research support / grants from Merck, Sharp & Dohme and speakers honorarium / fees from Berlin-Chemi/ Menarini, Eli Lilly & Co, Medscape, Medical Learning Institute, Merck, Sharp & Dohme, Novo Nordisk, Pfizer and Sanofi. He has also received board member / advisor panel payments from Astra Zeneca, Boehringer Ingelheim, Berlin-Chemi/ Menarini, Eli Lilly & Co, Merck, Sharp & Dohme, Novo Nordisk, Pfizer, Regor, Structure Therapeutics and Sun Pharma.

Date: Summer 2023